When a primary carcinoma of the cervix is treated by intracavitary radium, incidental irradiation changes may simulate carcinoma of the bladder. A cystophotograph from such a case showed what appeared to be a solid, invasive neoplasm with central calcified debris above the trigone; the edge of the lesion looked like a carcinoma and the surrounding mucosa had appearances suggesting infiltration. Total cystectomy was performed and a photograph of the specimen was not unlike a carcinoma but microscopic scrutiny failed to find any evidence of active carcinoma, the appearances being those of chronic inflammation, cystitis cystica and benign squamous metaplasia.
Even after looking at and comparing hundreds of cystophotographs it is very difficult to single out any one variant as indicative of recurrence or transition to metastasizing tumour. Photocystoscopy has been useful as a means of recording the appearances, response to treatment and progress of bladder neoplasms in the following ways:
(1) As a means ofrecording the living appearances of the original tumours for comparison with subsequent cystophotographs.
(2) To record the appearances, numbers and positions of subsequent neoplasms in follow-up work. An attempt to detect by comparison appearances suggesting a malignant trend have so far been disappointing.
(3) As a pictorial method of observing the response to treatment, especially in the case of carcinomata treated by cobalt beam therapy, but also as a means of assessing the efficacy of thiotepa and other chemical methods of dealing with active papillary neoplasms.
(4) As an aid to comparing the results of different forms of treatment.
(5) As a practical means of bringing the cystoscopic appearances of bladder neoplasms to the lecture theatre in order to stimulate thought and discussion. Cystophotographs seem to have emphasized the complexity of the problem instead of having led to a better understanding of the nature and behaviour of these interesting but difficult tumours.
There have been many difficulties. The photocystoscope used for this work (light conducted to bladder by quartz rod, from external source attached to eye-piece of cystoscope) is too cumbersome and unwieldy for routine use, and many improvements will have to be made.
The size of a tumour in a cystophotograph may be very misleading; the magnification or otherwise depends on the distance of the beak of the cystoscope from the tumour: a means of presenting the actual size of a tumour would be very useful in comparative work. As yet no cystophotographic method has been developed of representing the exact position of a tumour in the bladder. Work is proceeding in an attempt to overcome the many technical difficulties.
The Effect of Cyclophosphamide on Some Urinary Tract Tumours [Abstract] by Miles Fox chM FRCS (Department of Urology,
The General Infirmary at Leeds) Cyclophosphamide (Endoxan) has now been used extensively in the treatment of advanced malignant tumours. Results have varied. Tumours of the urinary tract belong to the most insensitive group. Treatment has usually consisted of a course amounting to a total of 5-10 g.
The effects of considerably larger doses of cyclophosphamide have been studied in 20 cases (Fox 1965) . Up to 50 g were given in one course. Two schedules of treatment were followed. In the first, 400-500 mg were given daily, intravenously, till the leucocyte count reached 1,000 per c.mm. By adjusting dosage, the leucocyte count was then allowed to rise slowly to about 2,000 per c.mm and after two months, up to 3,000-4,000 per c.mm. In the second regimen daily dosage was increased by 200 mg steps to a maximum of 800 mg. The leucocyte count was then allowed to rise as in the previous scheme. Toxic side-effects were not marked. Alopecia and initial anorexia were uniform. One patient developed a haemorrhagic lesion of the bladder mucosa. Platelets were not reduced below 50,000 per c.mm. Infection was not a problem. Patients with renal failure required smaller dosage.
Results are shown in Table 1 . Objective improvement was seen in 5 patients and another 5 showed subjective improvement. There were no permanent cures. Four cases were outstanding: Case 1 Man, aged 66 Anaplastic transitional cell carcinoma of bladder; multiple secondary deposits in liver with ascites. Within three weeks of starting therapy, there was marked diminution of liver size and the ascites disappeared with improvement of general condition. Four and a half weeks after starting treatment the patient died from a pulmonary embolus. Histology: Bladder and hepatic tumours: deposits were necrotic but some viable tumour cells were seen. Case 2 Man, aged 56 Anaplastic carcinoma prostate which had escaped from oestrogen control. Multiple bone secondary deposits with pain, cachexia and cedema of legs. Two weeks after starting treatment he was pain free and his appetite returned. Death occurred after seven months from a bleeding duodenal ulcer. Autopsy: Small fibrotic prostate; scattered nests of tumour cells were present among the extensive fibrous tissue. Case 3 Man, aged 53 Carcinoma of left kidney with secondary deposit in lung. Renal tumour explored and found irremovable because of size and fixity. Three weeks after commencing treatment, the lung deposit had markedly diminished in size. The renal mass became smaller and later impalpable. Function returned on intravenous pyelography. The patient died 11 months after starting treatment with a recurrent tumour in the liver. Case 4 Man, aged 57 Transitional cell carcinoma of bladder, widespread tumour deposits in skin and distant lymph nodes. Severe pain from pelvic nerve root involvement. Three weeks after commencing treatment pain disappeared and the lymph glands and skin deposits were no longer palpable. Patient remained well for eight weeks, then rapidly deteriorated and died from cerebral metastases.
Histology of an involved cervical gland eight days after commencing cyclophosphamide showed widespread destruction of tumour cells, swelling, pyknosis and fragmentation of nuclei and interstitial hamorrhage.
The results show that larger amounts of cyclophosphamide than previously recommended can be tolerated and that useful palliation can be achieved in some cases. REFERENCE Fox M (1965) 
